Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Drugs. 2022 Aug;82(12):1333-1339. doi: 10.1007/s40265-022-01761-9.
Cadonilimab (), a PD-1/CTLA-4 bi-specific antibody, is being developed by Akeso, Inc. for the treatment of a range of solid tumours, including cervical cancer, lung cancer, gastric/gastroesophageal junction cancer, oesophageal squamous cell cancer, liver cancer and nasopharyngeal cancer. Cadonilimab was approved in China in June 2022 for use in patients with relapsed or metastatic cervical cancer (r/mCC) who have progressed on or after platinum-based chemotherapy. This article summarizes the milestones in the development of cadonilimab leading to this first approval for the treatment of patients with r/mCC.
卡度尼利单抗（），一种 PD-1/CTLA-4 双特异性抗体，由和黄医药开发，用于治疗多种实体瘤，包括宫颈癌、肺癌、胃癌/胃食管交界处癌、食管鳞状细胞癌、肝癌和鼻咽癌。卡度尼利单抗于 2022 年 6 月在中国获批，用于治疗接受含铂化疗后疾病进展或复发的转移性宫颈癌（r/mCC）患者。本文总结了卡度尼利单抗的开发里程碑，最终使其获得了 r/mCC 适应证的首个批准。
